This renewal involves integrated and interdependent synthetic, mechanistic, structural, biochemical mode of action, computer modeling, collaborative and preclinical studies directed at the design, synthesis and advancement of fundamentally new and unique therapeutic leads and strategies directed at unsolved global human health problems: the eradication of HIV/AIDS, the treatment of Alzheimer's disease, and small molecule enhanced cancer immunotherapy. HIV is one of the most catastrophic pandemics to confront mankind. Current antiretroviral therapy (ART) addresses the active virus, allowing one to live with AIDS, but with cost, compliance, resistance and chronic chemo exposure challenges. ART is not curative. Reservoir cells incorporating genomically encoded provirus episodically resupply the active virus. Elimination of these reservoir cells if done with ART is thus one of the most promising strategies to eradicate HIV/AIDS. Modulation of protein kinase C (PKC) represents one of the best strategies to eliminate reservoir cells. PKC modulators are also implicated in cancer (in clinical trials), Alzheimer's disease (in clinical trials), and many other unmet therapeutic needs. The lead PKC modulator, bryostatin 1, is now in the clinic for AIDS eradication, Alzheimer's disease and cancer. It supply is nearly, if not, exhausted. A plan is provided to address the supply problem through the scalable synthesis of bryostatin 1. At the same time, plans are proposed to use combined experimental (REDOR and DNP solid state NMR) and computational approaches to produce the first structural and dynamic analysis of PKC-bryostatin analog complexes in a membrane environment. This first-of-its-kind integrated synthesis/solid state NMR/computational approach will allow us to understand at a molecular level the binding of current PKC modulators to the PKC regulatory domain. That information will then inform the design of new PKC modulators. Our current bryostatin analogs (bryologs) are superior to bryostatin in all studies conducted thus far including binding, cell, animal and ex viv studies on primary cells from patients. Our newest bryologs exhibit unprecedented PKC selectivities. These and new analogs will be advanced through a comprehensive series of assays conducted by us and our collaborators. The resulting bryologs represent preclinical leads proving thus far to be superior to bryostatin and because of their simplified structure are significantly more synthetically accessible than bryostatin.

Public Health Relevance

This project involves interconnected synthetic, mechanistic, structural, computer modeling, biochemical mode of action, preclinical, and collaborative studies directed at bryostatin 1, a compound now in clinic trials for the treatment of cancer and for two first-of-their-kind indications: the eradication of HIV/AIDS and the treatment of Alzheimer's disease. The supply of GMP bryostatin 1 is nearly if not exhausted, the future supply is at best uncertain, and it is likely that superior and more synthetically accessible agents could be identified. Plans to address these problems are presented including a) a strategy for the scalable synthesis of bryostatin 1, b) a first-of-its-kind integrated experimental and computational plan to understand at a structural and dynamic level how bryostatin binds to its protein kinase C (PKC) targets in a membrane environment, and c) the use of that knowledge to design, synthesize and preclinically advance potentially superior and more synthetically accessible analogs for the eradication of HIV/AIDS, treatment of Alzheimer's disease and small molecule enhanced immunotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA031845-40
Application #
9953951
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Fu, Yali
Project Start
1981-07-01
Project End
2021-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
40
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Stanford University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
McKinlay, Colin J; Benner, Nancy L; Haabeth, Ole A et al. (2018) Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc Natl Acad Sci U S A 115:E5859-E5866
Fernandes-Cunha, Gabriella M; McKinlay, Colin J; Vargas, Jessica R et al. (2018) Delivery of Inorganic Polyphosphate into Cells Using Amphipathic Oligocarbonate Transporters. ACS Cent Sci 4:1394-1402
Yang, Hao; Staveness, Daryl; Ryckbosch, Steven M et al. (2018) REDOR NMR Reveals Multiple Conformers for a Protein Kinase C Ligand in a Membrane Environment. ACS Cent Sci 4:89-96
Haabeth, Ole A W; Blake, Timothy R; McKinlay, Colin J et al. (2018) mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A 115:E9153-E9161
Khan, Tapan K; Wender, Paul A; Alkon, Daniel L (2018) Bryostatin and its synthetic analog, picolog rescue dermal fibroblasts from prolonged stress and contribute to survival and rejuvenation of human skin equivalents. J Cell Physiol 233:1523-1534
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
Albert, Brice J; Niu, Austin; Ramani, Rashmi et al. (2017) Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Sci Rep 7:7456
Ryckbosch, Steven M; Wender, Paul A; Pande, Vijay S (2017) Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes. Nat Commun 8:6
McKinlay, Colin J; Vargas, Jessica R; Blake, Timothy R et al. (2017) Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A 114:E448-E456
Wender, Paul A; Hardman, Clayton T; Ho, Stephen et al. (2017) Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358:218-223

Showing the most recent 10 out of 90 publications